Keep up with the latest news from CfPA, receive notifications about upcoming courses in your area of interest and more.
Protein Formulation and Stability
June 10-11, 2020
Course Offering 200610NJ2885
Course ID 2885
Who Should Attend?
This course is intended for professionals in the Pharmaceutical, Biopharmaceutical, Diagnostic and Vaccine industries , especially those working in departments such as: Chemistry, Biochemistry, Analytical, Engineering, and Biology. Chemists, Biochemist, Biologists, Formulators and Engineers working in product and process development and engineering will benefit greatly by attending this intensive training.
J. Jeff Schwegman, Ph.D., Founder and CEO, AB BioTechnologies
J. Jeff Schwegman, Ph.D. is the founder and chief executive officer of AB BioTechnologies where he manages the day to day operations of the company.
Dr. Schwegman received his BS in Biochemistry from Indiana University in 1992 and began working at Cook Imaging in Bloomington Indiana, where he gained experience in analytical, formulation and process development. In 1999 he began graduate study in the Department of Industrial and Physical Pharmacy at Purdue University under the direction of Dr. Steve Nail, where his focus of research involved studying changes in the physical structure of biological molecules during lyophilization. Dr. Schwegman received his Ph.D. from Purdue University in 2003 and returned to Bloomington where he worked at Baxter Pharmaceutical Solutions as a Research Scientist in the Pharmaceutical Development group. He specializes in speaking and consulting in parenteral pre-formulation, formulation, analytical, and lyophilization of both small molecules and large biomolecules.
In November 2005, he left Baxter and formed a life science company which specialized in developing new formulations and manufacturing processes for parenteral products. In February 2008, he formed AB BioTechnologies.
Dr. Marie-Eve Beaulieu,
Dr. Marie-Eve Beaulieu, Co-founder and Chief Scientific Officer, Peptomyc S.L.
is Co-founder and Chief Scientific Officer, Peptomyc S.L. Dr. Beaulieu has a strong background in R&D project management and coordinates the scientific team at Peptomyc. Her experience in biochemistry and peptide and protein structure and production enabled her to manage the in-house and outsourced scientific activities at Peptomyc since 2014. Marie-Eve developed the manufacturing protocols for OMO-103 (Peptomyc’s innovative proprietary cell-penetrating Myc inhibitor) at lab scale and oversaw its swift implementation at the manufacturing CRO. She also previously worked in the pharmaceutical industry (Theratechnologies Inc.) where she contributed to the development and study of novel formulations for a now commercialized peptide-based drug. Marie-Eve co-authored 4 patent applications, 19 peer-reviewed publications (two as corresponding author), was awarded 9 prizes for presentations and recently (June 2018), a young entrepreneur award.
ExitCertified (Attune formerly Microtek)
Raritan Plaza III
105 Fieldcrest Avenue, Suite 405
Edison , New Jersey
Phone: 800-207-9620 (for directions and parking info only)
PLEASE NOTE: Participants must make their own reservations; the cost of
hotel accommodation is not included in the course fee. Final hotel information
will be emailed to you in your confirmation package approximately 3 weeks
prior to the course start date.
Directions: Visit the Hotel Venue topic on our FAQ page.